Business Standard

Gland Pharma stock seen underperforming after acquiring France's Cenexi

Lack of near-term visibility on profitability for the core business is another concern about Indian firm

Gland Pharma
Premium

Gland Pharma's stock was down 5.4 per cent in trade on worries that the first overseas acquisition by Gland Pharma is margin dilutive and thus will weigh on earnings of the company

Ram Prasad Sahu Mumbai
Investors were not too enthused on Wednesday after Gland Pharma (Gland) said it is acquiring Cenexi, a French drug maker, at an enterprise value of 230 million euros (about Rs 2,000 crore).

Gland’s stock was down 5.4 per cent in trade on worries that the company’s first overseas acquisition dilutes margin and will weigh on earnings.

The operating profit margins of Cenexi, which makes ampoules, pre-filled syringes and vials and has expertise in sterile dosage forms, have improved over the last two years, but are still short of Gland’s profitability. Cenexi’s margins in the first half of calendar year 2022

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 30 2022 | 8:08 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com